What change do you most expect to see in the 340B program in the next year?
Reduced drug sales at 340B prices: 60%
Legislative changes to 340B program: 20%
HRSA lawsuit challenging 340B sales limitations by manufacturers: 20%
Shifting drug sales to 340B supportive manufacturers: 0%